20:07 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

Adcetris meets modified PFS endpoint in Phase III for first-line classical Hodgkin's lymphoma

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) reported data from the Phase III ECHELON-1 trial in 1,334 patients with stage III or IV classical Hodgkin's lymphoma not previously treated with systemic chemotherapy...
23:46 , Jun 26, 2017 |  BC Extra  |  Clinical News

Adcetris' Phase III Hodgkin's readout leaves investors wanting

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Adcetris brentuximab vedotin met the primary endpoint in the Phase III ECHELON-1 study as a first-line therapy for classical Hodgkin's lymphoma (cHL). Despite the...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Adcetris brentuximab vedotin: Additional Phase I data

Additional data from 47 evaluable patients with newly diagnosed Hodgkin's lymphoma in an open-label, dose-escalation, North American Phase I trial showed that the rate of complete remissions was 95% in patients receiving Adcetris plus ABVD...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

Adcetris brentuximab vedotin: Interim Phase I data

Interim data from an open-label, dose-escalation, North American Phase I trial in 44 patients with newly diagnosed Hodgkin's lymphoma showed that Adcetris plus ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) chemotherapy (n=25) led to complete remission...
07:00 , May 16, 2011 |  BioCentury  |  Product Development

Quelling Qualms about Revlimid

Updated Phase III data on the use of Celgene Corp. 's Revlimid lenalidomide as maintenance therapy in multiple myeloma have quelled fears that the risk of second primary malignancies might outweigh the drug's survival benefit....
07:00 , Mar 14, 2011 |  BC Week In Review  |  Clinical News

Yondelis trabectedin regulatory update

The U.K.'s NICE issued a second final appraisal determination (FAD) recommending against the use of Yondelis trabectedin from PharmaMar in combination with pegylated liposomal doxorubicin hydrochloride (PLDH) to treat relapsed ovarian cancer - its approved...
02:31 , Mar 11, 2011 |  BC Extra  |  Company News

NICE rebuffs Yondelis

The U.K.'s NICE issued draft guidance recommending against the use of Yondelis trabectedin from PharmaMar S.A. (Madrid, Spain) in combination with pegylated liposomal doxorubicin hydrochloride (PLDH) to treat relapsed ovarian cancer -- its approved indication....
08:00 , Feb 14, 2011 |  BC Week In Review  |  Clinical News

Yondelis trabectedin regulatory update

The U.K.'s NICE referred an appraisal of Yondelis trabectedin to treat relapsed ovarian cancer back to the appraisal committee after the Department of Health approved a patient access scheme submitted by PharmaMar following a final...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

Velcade bortezomib: Phase III data

The Phase III HOVON-65/GMMG-HD4 trial in 626 patients with newly diagnosed symptomatic MM showed that the Velcade-based treatment regimen led to superior PFS at 36 months vs. the standard chemotherapy treatment regimen (48% vs. 42%,...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Clinical News

Yondelis trabectedin regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Yondelis trabectedin in combination with pegylated liposomal doxorubicin hydrochloride (PLDH) to treat relapsed ovarian cancer - its approved indication. The recommendation...